Added to YB: 2024-01-15
Pitch date: 2024-01-15
ESPR [bullish]
Esperion Therapeutics, Inc.
+15.03%
current return
Author Info
No bio for this author
Company Info
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
Market Cap
$807.5M
Pitch Price
$3.06
Price Target
15.00 (+326%)
Dividend
N/A
EV/EBITDA
-53.12
P/E
-6.40
EV/Sales
4.33
Sector
Pharmaceuticals
Category
growth
Esperion Is Sitting On A Potential Blockbuster Drug
ESPR: NEXLIZET/NEXLETOL expands LDL market to 30M patients; $56M US sales (2022), more expected globally. Settlement+cost cuts aid 2025 breakeven goal. $300M mkt cap vs $400M 2025 rev target ($0.42 EPS). Key doc endorsements could mirror DexCom CGM diabetes success story. High risk/reward.
Read full article (8 min)